- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02603536
WelTelOAKTREE: Text Messaging to Support Patients With HIV/AIDS in British Columbia (WelTelOAKTREE)
Study Overview
Detailed Description
Purpose:
To provide a weekly text messaging intervention to 85 high risk HIV+ participants attending the Oak Tree HIV Clinic in order to improve medication adherence, attendance at appointments and subsequently, CD4 counts and HIV viral load values over a 1 year period.
Justification:
In Canada, around 65,000 people are living with HIV/AIDS, approximately 14,300 of whom are women. AntiRetroviral Therapy (ART) has led to enormous improvements in the health and survival of individuals with HIV. Moreover, by decreasing the amount of virus circulating in the body (viral load), HAART offers the possibility of treatment as a preventative measure. However, high levels of engagement in care, timely initiation of ARVs, and adherence to medication are required to maximize the benefits of HAART in order to prevent resistance, progression to AIDS, transmission or mortality. Unfortunately, engagement in ongoing HIV care can be poor, with one study from the United States (US) showing only 52% retention in care over 1 year. Further, adherence among high-risk populations is low, with women being less adherent partly due to their role as care providers for children and partners, potential abuse in partner relationships, fear of stigma, homelessness, and concerns regarding side effects. Conversely, active drug use (especially cocaine), lack of social supports, and depression are just a few of the variables that affect both men and women alike. Current methods of engagement in care have failed to overcome these barriers to adherence, which makes finding an effective adherence intervention critically important. Mobile health (mHealth), the use of mobile phone technology to deliver health care, is an emerging area of disease management that can assist in patient adherence to prolonged chronic treatment regimens and monitoring of care. A randomized controlled trial (WelTelKenya1), conducted by Dr. Richard Lester et. al, tested the clinical effectiveness of text message support for HIV treatment adherence in Kenya. WelTelKenya1, of which 67% were women, showed that patients receiving text message support had significantly higher rates of treatment adherence and viral suppression than patients who received standard care alone. In Canada, cell phone penetration exceeds 70% and is expected to reach 100% within the next decade. The WelTel system offers a clinical management model that can be carried out using standard services offered by cellular network providers with minimal additional infrastructure and is both flexible and scalable.
The investigators have completed one of the first studies of text messaging support for HIV care in Canada. The pilot study called WelTelBC1 involved 25 individuals from five patient groups 1) Non-suppressed (CD4 <200, VL >250); 2) Youth (ages 14-24); 3) Mature (Age ≥50); 4) English as a second language; and 5) Distance (those residing 3+ hours travel time from the clinic), who receive a weekly text message asking them "How are you?" Participants were then instructed to respond with "OK" or to let the investigators know if they had a problem. Participants who responded that they are "not okay" or did not respond were then followed up by a clinic nurse. The pilot study was designed to look at feasibility and acceptability of the weekly text messaging intervention in a Canadian HIV+ population, and resulted showed that the intervention was been perceived as beneficial among participants. In regards to acceptability, the pilot study has been extremely informative, and has enabled investigators to engage participants previously only seen sporadically; overcoming gaps that prevent optimal care and follow-up. In addition, we have seen from our pilot project, that to reach those in most need of a link to care we need to be prepared to provide cell phones and phone plan support to those without one (only 50% of those enrolled in our intervention owned a cell phone, and only 40% had unlimited text messaging - anecdotally these are the patients with whom engagement has most improved during the intervention). It is now critical to expand this program to all individuals at Oak Tree Clinic who could benefit and to study the efficacy of this intervention in engaging patients in care and improving adherence to HAART.
Research Method:
Participant Selection and Recruitment: A list of patients with a CD4 count ≤500 or previous prescription for antiretroviral therapy (other than for pregnancy) prior to the control year, as well as a detectable viral load (≥200) in the control year was assembled. The list was reviewed by the clinic physicians, nurse, pharmacist, dietician, counselor, outreach worker and social worker to determine which patients would benefit most from participating in the WelTel text messaging program (i.e. poor engagement in care, difficult to contact, poor or non-adherence to ARV therapy, advanced HIV infection/AIDS, vulnerable or socially isolated patients). A consensus based approach was used for patient selection. In addition, all 25 of the Oak Tree pilot study participants (WelTelBC1), were invited into the current study. Once nominated, when patients attended clinic for a clinical visit, they were introduced to the WelTel intervention concept. Those interested were approached by research staff for a full explanation. The intervention protocol was the same as that used for the WelTelBC1 pilot study at Oak Tree, developed through use of patient questionnaires as well as patient and health care worker focus groups/interviews at Oak Tree, and yet very similar to the intervention used in the initial WelTelKenya1 intervention. Following fully informed consenting with completion of consent forms, participants were provided with a cell phone with unlimited text messaging if they did not have one, or if they had their own cell phone, had their plan topped up to include unlimited text messaging service. Baseline clinical data including historical CD4 counts, and HIV viral loads were abstracted from patient charts.
Additionally, study participants were asked to complete a Quality of Life Assessment (QOL) questionnaire (the SF-12 questionnaire) at study entry (0 months), mid-way through study (6 months +/- 6 weeks) and at study exit (12 months +/- 6 weeks). The questionnaire consisted of 12 questions; was self-administered or interviewer administered; and took between 10 -15 minutes to complete.
Intervention:
The intervention protocol was the same as that used for the WelTelBC1 pilot study. This was modeled on the WelTelKenya1 intervention but adapted to the Oak Tree Clinic patient population through the use of patient questionnaires as well as patient and health care worker focus group and individual interviews. Each Monday, patients received a text message from a number not traceable to the clinic stating simply "How are you?" Patients were instructed to respond to the message if they are "OK" or to state that they have a problem. Messages were reviewed and triaged daily by our program research team member and in all cases of a negative or complex response other than OK, participants were contacted by the program nurse (patients were instructed that this is NOT an emergency service). Non-responders received a second text message on Wednesday at 12:00 pm (48 hours after the initial text sent out), and if there was no response, were contacted by the program nurse Wednesday afternoon or Thursday morning for follow-up.
Data Collection:
Participants wiwere asked their ethnicity at study enrolment. Participants were also asked to complete a 12 question QOL assessment questionnaire at study entry, mid-way through the study and at study end. Frequency of attendance in care was assessed from the outpatient clinic electronic booking system. Chart abstraction of clinical health status included: participant age (in years), housing status, current illicit drug use and postal code, CD4 counts and percentages, HIV viral loads, antiretroviral drug (ARV) regimen (including date of initiation or discontinuation), and degree of medication adherence (as determined from timing of ARV refills, and self-report), which was collected at baseline then at each clinical visit for the following one year. All available like data for one year prior (up to 2 years if in the Pilot Study) to enrollment in the WelTel program was alsocollected such that participants served as their own controls in the intervention (repeated measures study), and for the year following the intervention to assess the longevity of the intervention's impacts. Staff costs / savings were calculated by looking at Pharmacy, Nursing and Outreach worker time used both prior to and throughout the intervention. The planned duration of the intervention was one year, and of the study, 18 months. At that time data was analyzed and the program evaluated.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3N1
- Oak Tree Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- attendance at the Oak Tree Clinic for at least 1 year prior to study entry to permit historical comparison analysis and with at least one clinic visit in the preceding year from date of enrolment
- age ≥14 years
- CD4 count ≤500 cells/mm3 or previous prescription for antiretroviral therapy (other than for pregnancy) prior to the control year, (indicating clinical indication for HIV therapy existed during the control year)
- any detectable viral load (≥200 copies/mL) in the control year OR is one of the 25 participants in the pilot study, WelTelBC1 (H11-03003), and who when approached for consent into the current study, chooses to participate
Exclusion Criteria:
- attendance at the Oak Tree Clinic for less than one year prior to study entry
- age <14 years
- consensus by clinical team that patient does NOT fit high-risk criteria as listed
- lives in an area where cell phone service is not available
- unable to communicate via the text-messaging system
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vulnerable or pilot participant
In addition to standard care, WelTel will send a weekly text message to participants in this arm for a one year period.
Participants will be requested to respond to the outgoing message "How are you?"
within 48 hours; they may respond that they are doing well or that they have a problem.
A clinician will call to follow-up with all participants who respond indicating a problem or who do not respond within 48 hours.
|
An evidence-based, text messaging solution for improving patient adherence.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Increased viral load/proportion of HIV viral load tests showing virologic suppression (< 40copies/ml)
Time Frame: Two years
|
Measured using lab results available in the patient charts in the intervention year compared to the year prior to enrollment.
|
Two years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of hours spent by health care providers for this intervention
Time Frame: Two years
|
To inform future program development
|
Two years
|
Improved engagement
Time Frame: Two years
|
Measured using attendance at outpatient visits in the intervention year compared to the year prior to enrollment.
|
Two years
|
Increased CD4 counts
Time Frame: Two years
|
Measured using lab results available in the patient charts in the intervention year compared to the year prior to enrollment.
|
Two years
|
Improved antiretroviral medication adherence
Time Frame: Two years
|
Measured using patient self-report data available in the patient charts in the intervention year compared to the year prior to enrollment.
|
Two years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Melanie Murray, MD,PhD,FRCPC, BC Women's Hospital & Health Centre
Publications and helpful links
General Publications
- El Joueidi S, Bardosh K, Musoke R, Tilahun B, Abo Moslim M, Gourlay K, MacMullin A, Cook VJ, Murray M, Mbaraga G, Nsanzimana S, Lester R. Evaluation of the implementation process of the mobile health platform 'WelTel' in six sites in East Africa and Canada using the modified consolidated framework for implementation research (mCFIR). BMC Med Inform Decis Mak. 2021 Oct 26;21(1):293. doi: 10.1186/s12911-021-01644-1.
- Campbell AR, Kinvig K, Cote HC, Lester RT, Qiu AQ, Maan EJ, Alimenti A, Pick N, Murray MC. Health Care Provider Utilization and Cost of an mHealth Intervention in Vulnerable People Living With HIV in Vancouver, Canada: Prospective Study. JMIR Mhealth Uhealth. 2018 Jul 9;6(7):e152. doi: 10.2196/mhealth.9493.
- King E, Kinvig K, Steif J, Qiu AQ, Maan EJ, Albert AY, Pick N, Alimenti A, Kestler MH, Money DM, Lester RT, Murray MCM. Mobile Text Messaging to Improve Medication Adherence and Viral Load in a Vulnerable Canadian Population Living With Human Immunodeficiency Virus: A Repeated Measures Study. J Med Internet Res. 2017 Jun 1;19(6):e190. doi: 10.2196/jmir.6631.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- F12-05361
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
-
University of Maryland, BaltimoreWithdrawnHiv | Kidney Transplant | HIV Reservoir | CCR5United States
Clinical Trials on WelTel
-
University of British ColumbiaNational Institute of Mental Health (NIMH)Unknown
-
Queen's UniversityMuhimbili University of Health and Allied Sciences; Kilimanjaro Clinical Research...Not yet recruiting